acute ST-segment elevation myocardial infarction
Conditions
Interventions
intramyocardial hemorrhage group:none
non-intramyocardial hemorrhage group:none
Sponsors
First Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. aged 18-75 years; 2. meet the ECG acute STEMI standard (typical chest pain and ST segment elevation on admission): persistent chest pain =30 minutes; ST segment elevation of ECG in at least two consecutive limb leads is =0.1mv or chest lead is = 0.2 mv; or new complete left bundle branch block; 3. successful PCI stent implantation within 24 hours after symptom onset; 4. volunteered to participate in this trial and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Hemodynamic instability or cardiogenic shock; Refractory angina pectoris; Life-threatening arrhythmia; Complicated with acute heart failure; Patients with persistent ventricular arrhythmia, atrial fibrillation or severe valvular disease complicated with poor drug control need anticoagulant therapy; 2. Severe liver and renal insufficiency (serum creatinine > 221 µ mol/L, ALT/AST more than 5 times higher than the normal high limit); 3. Complicated with serious infection; 4. Those who have a history of tumor or are suffering from tumor, or have precancerous lesions confirmed by pathological examination; 5. Patients with active peptic ulcer disease, anemia, coagulation dysfunction and hematopoietic diseases; 6. Evidence of known heart diseases such as previous history of myocardial infarction or PCI, hypertrophic cardiomyopathy, dilated cardiomyopathy, acute pericarditis, subacute infective endocarditis, etc. 7. Clinical diagnosis of pericardial effusion, pleural effusion, or images showing pericardial effusion (greater than 50ml or 3mm and above) or pleural effusion (greater than 200ml or 10 mm); 8. Any contraindications of CMR, such as: pacemaker implanted in the past, implantable defibrillator, claustrophobia, intracranial metal implant, etc.; 9. Pregnant or lactating women; 10. Severe nervous system diseases (Alzheimer's disease, progressive Parkinson's syndrome, etc.); 11. Can't accept regular examination and follow-up: the researcher judges that the survival time is less than 2 years, or the subject can't complete this study or can't comply with the requirements of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R2* mapping quantitative parameters;Serum quantitative parameters; | — |
Secondary
| Measure | Time frame |
|---|---|
| LV strain parameters;Late gadolinium enhancement parameters; | — |
Countries
China
Contacts
Public ContactTing Liu
First Hospital of China Medical University
Outcome results
None listed